BG
ACRS icon

Bollard Group’s Aclaris Therapeutics ACRS Stock Holding History

Bollard Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.28M Hold
431,631
– – 0.07% 81
2026
Q1 		$1.62M Sell
431,631
-372,814
-46% -$1.26M 0.05% 96
2025
Q4 		$2.42M Sell
804,445
-421,031
-34% -$1.06M 0.06% 79
2025
Q3 		$2.33M Sell
1,225,476
-126,800
-9% -$221K 0.05% 83
2025
Q2 		$1.92M Sell
1,352,276
-71,900
-5% -$97.3K 0.04% 89
2025
Q1 		$2.18M Buy
+1,424,176
New +$3.04M 0.06% 83

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Bollard Group's ACRS Position: Q2 2026 in Review

Bollard Group held its Aclaris Therapeutics (ACRS) position steady in Q2 2026 at 431,631 shares worth $2.28M. The position accounts for 0.07% of the portfolio, ranked #81.

Bollard Group first reported a position in ACRS in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.42M in Q4 2025. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Bollard Group held 431,631 shares of Aclaris Therapeutics worth $2.28M as of Q2 2026.
  • Bollard Group left its Aclaris Therapeutics share count unchanged in Q2 2026.
  • Aclaris Therapeutics made up 0.07% of Bollard Group's portfolio in Q2 2026, its #81 holding.
  • Bollard Group first reported a position in Aclaris Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Bollard Group's Aclaris Therapeutics position peaked at $2.42M in Q4 2025.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Bollard Group's 13F filing for Q2 2026, filed 12 Aug 2026.